Assembly Biosciences, Inc. ASMB today announced Initiation of Phase 1b clinical study of its drug candidate ABI-H3733 for Chronic Hepatitis B Virus Infection
The Phase 1b clinical trial will evaluate the safety, pharmacokinetics and antiviral activity of 3733 in adults with chronic HBV (cHBV) infection.
This trial is supported by the results from previous Phase 1a study of 3733 showing a favorable safety and pharmacokinetic profile and will evaluate a new tablet formulation with the potential for convenient once-daily dosing.
ABI-H3733 (3733) is an investigational next-generation, highly potent core inhibitor.
John McHutchison, AO, MD, chief executive officer and president, commented : "This study initiation serves as an important milestone in the clinical development program for 3733, a promising candidate that has demonstrated increased potency against both HBV core inhibitor mechanisms and against cccDNA formation in particular, and advances our strategy to pursue finite and curative HBV therapies."
The company is scheduled to highlight additional details about the new tablet formulation of 3733 in a poster accepted for presentation at the Annual Meeting of the European Association for the Study of the Liver (EASL), will be held in London on June 22-26, 2022.
Assembly Biosciences shares are currently trading at $1.99, down 3 percent from its previous close of $2.05 on a volume of 89.15 thousand shares.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.